ClinicalTrials.Veeva

Menu

Comparison of Diagnostic Performances of 3D FLAIR, DIR and PSIR Sequences in Optic Neuritis (Optic-Neuritis)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Multiple Sclerosis
Demyelinating Diseases

Study type

Observational

Funder types

Other

Identifiers

NCT06494228
9024 (Other Grant/Funding Number)

Details and patient eligibility

About

Ultimately improve the care of patients suffering from multiple sclerosis (1st cause of acquired non-traumatic disability in adults) and NMO spectrum diseases by using more efficient MRI sequences than the FLAIR sequence commonly used in detection of optic neuritis.

In the literature, many studies have already focused on comparing the sensitivity of detection of white matter demyelination plaques using FLAIR, PSIR or DIR sequences.

Some authors have shown better sensitivity of the PSIR sequence in the detection of demyelinating lesions of the marrow in multiple sclerosis compared to conventional sequences.

Others have shown better performance of the combined use of PSIR and DIR sequences compared to the FLAIR sequence in the detection of cortical lesions in multiple sclerosis.

However, in the context of optic neuritis, few comparative studies comparing these three sequences have been carried out:

A 2022 study showed better diagnostic sensitivity of optic neuritis of the DIR sequence compared to the FLAIR sequence.

A possible better diagnostic performance of a sequence not used in current practice in the detection of optic neuritis (PSIR and DIR sequences), would be possible to justify their use on a larger scale and ultimately improve patient care.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major subject (≥18 years old)
  • Subject suffering from multiple sclerosis or an NMO spectrum disease
  • Subject having received an MRI including 3D FLAIR, 3D DIR and 3D PSIR sequences
  • Brain MRIs of eligible subjects acquired between April 1, 2019 and November 30, 2021.
  • No opposition to the reuse of its data for scientific research purposes.

Exclusion criteria

  • Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.
  • Artifacts not allowing satisfactory interpretation

Trial contacts and locations

1

Loading...

Central trial contact

François-Daniel ARDELLIER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems